Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock? [Yahoo! Finance]
Beam Therapeutics Inc. (BEAM)
US:NYSE Investor Relations:
beamsuntory.com/about/shareholder-information/reports
Company Research
Source: Yahoo! Finance
This compares to the stock's 20% gain over the past four weeks. The stock rallied as optimism grew over the company's promising pipeline of gene editing therapies, which have been developed based on its proprietary base editing technology. The company is advancing its base editing technology across three disease area portfolios, namely, hematology, immunology/oncology and genetic diseases. Several clinical milestones are expected later in 2024. This company is expected to post quarterly loss of $1.13 per share in its upcoming report, which represents a year-over-year change of -4.6%. Revenues are expected to be $14.12 million, down 29.8% from the year-ago quarter. While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. For Beam Therapeutics, the consensus EPS estimate for the quarter has remained
Show less
Read more
Impact Snapshot
Event Time:
BEAM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BEAM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BEAM alerts
High impacting Beam Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BEAM
News
- Beam Therapeutics Inc. (NASDAQ: BEAM) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.MarketBeat
- Beam Therapeutics Inc. (NASDAQ: BEAM) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $27.00 price target on the stock.MarketBeat
- Beam Therapeutics Inc. (NASDAQ: BEAM) had its price target raised by analysts at Stifel Nicolaus from $66.00 to $69.00. They now have a "buy" rating on the stock.MarketBeat
- Glycogen Storage Disease Type 1a (GSD-1a) Treatment and Market Landscape Report 2024 [Yahoo! Finance]Yahoo! Finance
- Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
BEAM
Earnings
- 5/7/24 - Beat
BEAM
Sec Filings
- 10/17/24 - Form SC
- 10/16/24 - Form 4
- 10/15/24 - Form 144
- BEAM's page on the SEC website